search

Paul Spagnuolo, a world leader in bioinnovation research, will be honoured for his work on an avocado-derived lipid with potent antileukemia activity with the first LIST International Award in Bioinnovation.

With the LIAB Award, the Luxembourg Institute of Science and Technology (LIST) seeks to connect Luxembourg to world-leading researchers in the fields of biology, ecology, circular economy, health sciences and food sciences. Endowed with 10,000 euros and sponsored by PM-International, a Luxembourg-based nutrition company specialised in premium dietary supplements and health products, the prize will be awarded at the Halle des Poches à Fonte in Belval on November 23 2017 at 19h00.

TOP-FLIGHT CANDIDATES

Earlier this year, LIST launched a call for proposals to the international research community to highlight their innovative work submitted or published after January 1 2014 in domains such as the bioavailability of nutrients, nutrient transport and nutrient effectiveness on a cellular level. More than thirty world-renowned researchers responded to this call.

All applications were reviewed by a jury composed of academics from LIST as well as international experts from renowned universities in the field, such as the University of Groningen in the Netherlands, the University of Applied Sciences Upper Austria, as well as bioinnovation professionals, with a pharmacist and a general medical practitioner, the latter also working at PM-International.

A CANADIAN LAUREATE REWARDED

Among the applications received, it was the outstanding work of Paul Spagnuolo, Associate Professor within the Department of Food Science at the University of Guelph in Canada, which appealed most to the jury members. He was chosen for the prize of 10,000 euros thanks to his paper on anticancer nutraceuticals (nutrients with pharmaceutical properties) published in June 2015 in Cancer Research, a prestigious cancer research journal.

In his article “Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death”, Paul Spagnuolo unveiled his work on Avocatin B, an avocado-derived lipid with potent anti-leukemia activity. Exploring a potential answer to cancer, his article highlights the cell and molecular mechanisms by which Avocatin B selectively targets and eliminates leukemia stem cells. This work, which received much international attention at the time of its publication, has since provided the framework for studies that are now moving Avocatin B into human testing for bioactivity.

Paul Spagnuolo is a renowned researcher in the field. Author of over 30 peer-reviewed publications and a Principal Investigator since March 2012, he has secured more than 2 million dollars in funding from Canadian and international agencies as well from industry. At the University of Guelph since 2016, Paul Spagnuolo runs a laboratory that is uniquely positioned amongst world leaders in food, nutrition and nutraceutical research.

Read more

Unlocking funding for digital health technologies

18-07-2024

The 2024 European Digital Healthtech Conference explored the topic of funding for digital health technologies from the investor’s perspective.
Read more

Fit 4 Start #15 call for applications open

15-07-2024

For its 15th edition, Luxembourg’s startup accelerator Fit 4 Start is accepting applications from innovative healthtech, digital, and space enterprises worldwide. Deadline to apply: 12 August 2024.
Read more

“Efficient support, impressive open-mindedness”

09-07-2024

Japanese deeptech startup Thermalytica speaks about launching its innovative insulation technology from Luxembourg for European market expansion.
Read more

Building bridges for startup market expansion

05-07-2024

A partnership between Tsukuba City in Japan and Luxembourg paves the way for startups from the two countries to penetrate the European and Asian markets.
Read more

Strengthening Luxembourg-South Korea business relations

03-07-2024

Luxembourg’s new embassy in Seoul was inaugurated on 3 July 2024 during a government working visit to South Korea focusing on the economy and research.
Read more

Resources all news

Fermer